| Nicholas Michael Absalom, MD | |
|
7259 S Bingham Junction Blvd, Midvale, UT 84047-4860 | |
| (801) 264-6400 | |
| Not Available |
| Full Name | Nicholas Michael Absalom |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 17 Years |
| Location | 7259 S Bingham Junction Blvd, Midvale, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770744112 | NPI | - | NPPES |
| 3115814 | Medicaid | NH |
| Facility Name | Location | Facility Type |
|---|---|---|
| Renown Regional Medical Center | Reno, NV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Community Care Services Llc | 1951324318 | 385 |
News Archive
Children entering kindergarten with elementary math and reading skills are the most likely to do well in school later, even if they have various social and emotional problems, say researchers who examined data from six studies of close to 36,000 preschoolers.
The international science community is not doing enough to track the many avian influenza viruses that might cause the next pandemic, a UC Davis researcher says in the journal Nature.
Critical Path Institute (C-Path) announced today that the Biomarker Qualification Program (BQP) at the Center for Drug Evaluation and Research (CDER) from the U.S. Food and Drug Administration (FDA) issued a positive response to the Qualification Plan (QP) for glutamate dehydrogenase (GLDH) as a safety biomarker for drug-induced liver injury (DILI), developed by C-Path's Predictive Safety Testing Consortium (PSTC) and Duchenne Regulatory Science Consortium (D-RSC).
Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen and other gas delivery, today announced the initiation of a Phase 1b study designed to evaluate the safety of MP4CO treatment in patients with sickle cell disease.
› Verified 1 days ago
| Entity Name | Community Care Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720031768 PECOS PAC ID: 1951324318 Enrollment ID: O20060111000900 |
News Archive
Children entering kindergarten with elementary math and reading skills are the most likely to do well in school later, even if they have various social and emotional problems, say researchers who examined data from six studies of close to 36,000 preschoolers.
The international science community is not doing enough to track the many avian influenza viruses that might cause the next pandemic, a UC Davis researcher says in the journal Nature.
Critical Path Institute (C-Path) announced today that the Biomarker Qualification Program (BQP) at the Center for Drug Evaluation and Research (CDER) from the U.S. Food and Drug Administration (FDA) issued a positive response to the Qualification Plan (QP) for glutamate dehydrogenase (GLDH) as a safety biomarker for drug-induced liver injury (DILI), developed by C-Path's Predictive Safety Testing Consortium (PSTC) and Duchenne Regulatory Science Consortium (D-RSC).
Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen and other gas delivery, today announced the initiation of a Phase 1b study designed to evaluate the safety of MP4CO treatment in patients with sickle cell disease.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nicholas Michael Absalom, MD 8750 Mediterranean Dr, Dallas, TX 75238-3742 Ph: () - | Nicholas Michael Absalom, MD 7259 S Bingham Junction Blvd, Midvale, UT 84047-4860 Ph: (801) 264-6400 |
News Archive
Children entering kindergarten with elementary math and reading skills are the most likely to do well in school later, even if they have various social and emotional problems, say researchers who examined data from six studies of close to 36,000 preschoolers.
The international science community is not doing enough to track the many avian influenza viruses that might cause the next pandemic, a UC Davis researcher says in the journal Nature.
Critical Path Institute (C-Path) announced today that the Biomarker Qualification Program (BQP) at the Center for Drug Evaluation and Research (CDER) from the U.S. Food and Drug Administration (FDA) issued a positive response to the Qualification Plan (QP) for glutamate dehydrogenase (GLDH) as a safety biomarker for drug-induced liver injury (DILI), developed by C-Path's Predictive Safety Testing Consortium (PSTC) and Duchenne Regulatory Science Consortium (D-RSC).
Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen and other gas delivery, today announced the initiation of a Phase 1b study designed to evaluate the safety of MP4CO treatment in patients with sickle cell disease.
› Verified 1 days ago
Amie Jo Aslami, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 7434 S State St, Midvale, UT 84047 Phone: 801-245-9283 | |
Bryan S Maulden, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1225 Fort Union Blvd Ste 215, Midvale, UT 84047 Phone: 801-501-4350 | |
Elyse Frances Coolidge, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 7309 S 180 W, Midvale, UT 84047 Phone: 801-569-2153 | |
Angelique D. Goodhue, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 7434 S State St, South Valley Mental Health, Midvale, UT 84047 Phone: 801-566-4432 | |
Richard A Segal, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1225 Fort Union Blvd Ste 215, Midvale, UT 84047 Phone: 801-501-4350 |